Mabqi will participate in BIO-Europe 2026, taking place from November 9–11 in Cologne, Germany.
Sylvain Yon, CEO of Mabqi, will attend the event to meet with potential partners and discuss collaboration opportunities around Mabqi’s antibody discovery capabilities and proprietary pipeline.
These discussions will focus on:
• Our pipeline of differentiated targeted therapies in cancer
• Strategic partnerships supporting the development of next-generation antibody therapeutics
• Expertise in conditionally active and conventional antibodies thanks to our LiteMab antibody discovery studio
Meetings with Sylvain Yon can be scheduled through the partneringONE platform.
Mabqi looks forward to connecting with industry leaders, investors and innovators in Cologne and contributing to the development of new biopharmaceutical partnerships.
BIO-Europe is one of the leading international partnering events for the biopharmaceutical industry, bringing together biotech companies, pharmaceutical groups, investors and service providers to explore new collaboration opportunities and advance innovative therapeutic programs.
